Clinical Trials in Yinchuan, Ningxia
65 recruiting
Showing 1–20 of 59 trials
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pediatric Migraine
Pfizer2,100 enrolled109 locationsNCT04649242
Recruiting
Phase 2
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
Breast Cancer Brain Metastases
Shanghai Pharmaceuticals Holding Co., Ltd52 enrolled25 locationsNCT05872347
Recruiting
Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled39 locationsNCT05458219
Recruiting
Not Applicable
Effect of Lateral Versus Supine Positions on Postoperative Hypoxemia
Postoperative Hypoxemia
General Hospital of Ningxia Medical University960 enrolled1 locationNCT07545642
Recruiting
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis
bone metastasisPSMA PETProstate Cancer (Diagnosis)+4 more
Xijing Hospital1,000 enrolled9 locationsNCT07553754
Recruiting
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
Treatment ResponseHigh-risk Prostate CancerPSMA PET+1 more
Xijing Hospital110 enrolled9 locationsNCT07553780
Recruiting
Phase 3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Cardiovascular Disease
Amgen406 enrolled40 locationsNCT07293260
Recruiting
Phase 2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Lupus Nephritis
Novartis Pharmaceuticals240 enrolled103 locationsNCT05268289
Recruiting
Phase 3
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Non-small Cell Lung Cancer
RemeGen Co., Ltd.574 enrolled66 locationsNCT07416474
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited132 enrolled30 locationsNCT07327229
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Phase 2
JS207 Combination Therapy in Triple-negative Breast Cancer
Triple-Negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.80 enrolled22 locationsNCT07045311
Recruiting
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
Molecular ImagingSuspected Prostate CancerTreatment-naive Prostate Cancer
Xijing Hospital1,000 enrolled9 locationsNCT07531329
Recruiting
Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
Advanced Liver Cancer
Abbisko Therapeutics Co, Ltd200 enrolled32 locationsNCT04906434
Recruiting
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Clinically Significant Prostate Cancer
Xijing Hospital1,700 enrolled10 locationsNCT07492927
Recruiting
China Cognition and Aging Study
Mild Cognitive Impairment (MCI)Alzheimer Disease, Late OnsetFamilial Alzheimer Disease (FAD)+3 more
Capital Medical University100,000 enrolled65 locationsNCT03653156
Recruiting
The Chinese Familial Alzheimer's Network
Alzheimer DiseaseFamilial Alzheimer Disease (FAD)
Capital Medical University40,000 enrolled65 locationsNCT03657732
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 3
Optimizing Early Nutrition Support in Severe Stroke-2
severe strokeAcute StrokeDysphagia
Wen Jiang-3546 enrolled30 locationsNCT05998902